EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating Tumor DNA Detection for Recurrence Monitoring of Stage I Non‐Small Cell Lung Cancer Treated With Microwave Ablation

Lin Cheng, Sheng Xu iD, Yu-Feng Wang, Sheng-Wei Li, Bin Li, Xiao-Guang Li iD

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.15534 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Lin Cheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese A…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Circulating Tumor DNA, Lung Neoplasms, Microwaves. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chinese Academy of Medical Sciences Clinical and Translational Medicine Research Special No.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

As microwave ablation continues to be used in patients with inoperable stage I non‐small cell lung cancer (NSCLC), it is particularly important to monitor efficacy. Whether plasma ctDNA detection can predict its efficacy should be illustrated.

Methods

We recruited 43 patients with inoperative stage I NSCLC, all of whom underwent biopsy‐synchronous microwave ablation (MWA). Peripheral blood samples were collected at baseline ( n = 43), within 1 h post‐MWA ( n = 28), and at the landmark time point ( n = 26) for MRD detection. Clinical outcomes were analyzed using Kaplan–Meier survival analysis.

Results

Patients with undetectable ctDNA at baseline ( p = 0.042) and within 1 h after MWA ( p = 0.023) had better clinical outcomes. In particular, patients with undetectable ctDNA at the 1‐h post‐MWA time point did not experience recurrence. Detection of ctDNA at the landmark time point is considered an independent risk factor for prognosis and is strongly correlated with clinical outcomes ( p = 0.001), the median time to recurrence indicated by ctDNA was 4.9 months earlier compared to imaging. The clinical outcomes of patients with ctDNA clearance were similar to those with no ctDNA ( p = 0.570). Risk stratification indicated that patients with persistent ctDNA had worse clinical outcomes compared to those who never had detectable ctDNA ( p = 0.004).

Conclusion

Our findings suggest that ctDNA monitoring can assist in predicting clinical outcomes in stage I NSCLC treated with microwave ablation. Patients with undetectable ctDNA within 1 h after MWA are determined to be clinically cured. Risk stratification based on ctDNA test results helps to differentiate high‐risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCirculating Tumor DNALung NeoplasmsMicrowavesNeoplasm Recurrence, LocalBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedNeoplasm StagingPrognosis

Stichwörter der Autor:innen

NSCLCctDNAefficacymicrowave ablation

Substanzen

Circulating Tumor DNABiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Minimally Invasive Tumor Therapies Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
  • Medical School, University of Chinese Academy of Sciences, Beijing, China.

ORCID-Profile: Sheng Xu, Xiao-Guang Li

Förderung

  • Chinese Academy of Medical Sciences Clinical and Translational Medicine Research Special No

Zitieren

APA

Cheng, L., Xu, S., Wang, Y. F., Li, S. W., Li, B., & Li, X. G. (2025). Circulating Tumor DNA Detection for Recurrence Monitoring of Stage I Non‐Small Cell Lung Cancer Treated With Microwave Ablation. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15534

Vancouver

Cheng L, Xu S, Wang YF, Li SW, Li B, Li XG. Circulating Tumor DNA Detection for Recurrence Monitoring of Stage I Non‐Small Cell Lung Cancer Treated With Microwave Ablation. Thoracic Cancer. 2025. doi:10.1111/1759-7714.15534

BibTeX
@article{Cheng2025,
  author = {Cheng, Lin and Xu, Sheng and Wang, Yu-Feng and Li, Sheng-Wei and Li, Bin and Li, Xiao-Guang},
  title = {Circulating Tumor DNA Detection for Recurrence Monitoring of Stage I Non‐Small Cell Lung Cancer Treated With Microwave Ablation},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.15534}
}
Kostenlos starten →